News

Kaléo Enters Into Licensing Agreement With Valeo Pharma For The Canadian Rights to ALLERJECT®(epinephrine injection, USP)

Richmond, Va – Kaléo, a privately held U.S. pharmaceutical company, today announced that

it has entered into a ten-year License, Supply, and Commercialization agreement with Valeo Pharma, a

Canadian pharmaceutical company, for the Canadian rights to ALLERJECT® (epinephrine injection, USP) for the

treatment of severe allergic reactions.

“Patients with life threatening allergies across Canada deserve access to this innovative and potentially

lifesaving product,” said Kaléo President and CEO Ronald Gunn. “Valeo Pharma’s sales force, relationships with

the healthcare community, and commitment to patients make them the ideal partner for ALLERJECT.”

For more information please click here.

Recent News

10/16/2025

Phlow Corp. Selected by the U.S. Food and Drug Administration Commissioner’s First-Ever National Priority Voucher Pilot Program to Advance Manufacturing of a Critical Essential Medicine in America

Phlow Corp., a leading American advanced pharmaceutical contract development and manufacturing organization (CDMO), today announced that the active pharmaceutical ingredient for ketamine will be included in the first-ever U.S. Food and Drug Administration (FDA) Commissioner’s National Priority Voucher (CNPV) Pilot Program. This designation recognizes Phlow’s leadership in advancing domestic manufacturing of essential and life-changing medicines …

10/16/2025

Civica To Launch Long-Acting Insulin Glargine in the US in January 2026

Non-profit pharmaceutical company Civica will launch an affordable long-acting insulin – insulin glargine-yfgn in pre-filled pens – at the lowest list price in the current long-acting insulin market. Civica insulin glargine will be available in the United States beginning January 1, 2026. In California, the product will carry the “CalRx” brand. “Civica will provide insulin …

10/13/2025

InBio Secures $3.5 Million NIH Grant to Advance Allergy Research

InBio, a global leader in allergy research, was recently awarded a $3.5 million R01 grant from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). This funding supports a groundbreaking initiative to develop innovative immunotherapeutic tools targeting allergens from house dust mites, cats, and dogs—major contributors to …